Longeveron (LGVN) Total Non-Current Liabilities (2022 - 2026)
Longeveron (LGVN) posted quarterly Total Non-Current Liabilities of $838000.0 for Q1 2026, down 13.25% year-over-year from $966000.0 in Q1 2025, and up 67.94% quarter-over-quarter from $499000.0 in Q4 2025.
Longeveron (LGVN) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
Longeveron's Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $838000.0 for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 13.25% year-over-year to $838000.0; the TTM figure through Mar 2026 stood at $838000.0 (down 13.25% YoY), while the FY2025 annual figure was $499000.0, down 54.18% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $838000.0, up from $499000.0 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $2.0 million in Q4 2022, with the low at $499000.0 in Q4 2025.
- The 5-year median for Total Non-Current Liabilities is $1.2 million (2024), against an average of $1.2 million.
- The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities sank 54.18% in 2025, then slipped 13.25% in 2026.
- Longeveron's Total Non-Current Liabilities stood at $2.0 million in 2022, then decreased by 29.05% to $1.4 million in 2023, then slipped by 24.79% to $1.1 million in 2024, then tumbled by 54.18% to $499000.0 in 2025, then jumped by 67.94% to $838000.0 in 2026.
- Business Quant data shows LGVN's Total Non-Current Liabilities at $838000.0 in Q1 2026, $499000.0 in Q4 2025, and $651000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 778,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 778,000.00 |
| Mar 31, 2026 | 838,000.00 |
| Dec 31, 2025 | 499,000.00 |
| Sep 30, 2025 | 651,000.00 |
| Jun 30, 2025 | 809,000.00 |
| Mar 31, 2025 | 966,000.00 |
| Dec 31, 2024 | 1.09 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Jun 30, 2024 | 1.27 Mn |
| Mar 31, 2024 | 1.36 Mn |
| Dec 31, 2023 | 1.45 Mn |
| Sep 30, 2023 | 1.60 Mn |
| Jun 30, 2023 | 1.75 Mn |
| Dec 31, 2022 | 2.04 Mn |